Fabry disease (FD) is a rare X-linked recessive disorder caused by mutations in the gene encoding the lysosomal enzyme α-galactosidase A (α -Gal A). The resulting deficient α -Gal A activity leads to progressive accumulation of glycosphingolipids, predominantly globotriaosylceramide (GL-3) in the lysosomes of many different cell types throughout the body [1]. The manifestations of this complex metabolic disease are progressive and multisystemic, culminating in life-threatening renal, cardiac and cerebrovascular manifestations [2].

Although angiokeratomas could serve as a key diagnostic sign, they are not considered as a reliable prognostic marker as they are often not directly related with systemic morbidity [5]. Besides, although clinical trials have shown the efficacy and safety of enzyme replacement therapy (ERT) with improvement of clinical symptoms, the reports on its effect on skin lesions are limited and contradictory [6-9].

Case Presentation

A 7-year-old boy was admitted to the University Children’s Hospital Rijeka with a two-year history of failure to thrive and widespread skin lesions. Before the admission, he was seen by numerous physicians regarding these signs, without the working diagnosis. On physical examination, the boy’s weight and height were below the 5th percentile age curve. Close inspection of the skin revealed widespread angiokeratomas, most dense over the umbilical region (Figure 1a and 1b). Routine blood tests, coagulation and platelet function studies were unremarkable. Microscopic examination of a skin biopsy specimen confirmed presence of angiomata within the epidermis and dermis. Urine analysis showed minimal proteinuria. Given the presence of angiokeratoma and albuminuria, FD was included in the differential diagnosis. α-galactosidase A activity assay (8% of normal activity) and subsequent genetic studies (p.W81X mutation in the GLA gene) verified the diagnosis of FD.

Comprehensive assessment was performed to determine the extent of organ involvement. Glomerular filtration rate was normal. Kidney biopsy showed changes in the glomerular, tubulointerstitial...
and vascular compartments. Electron microscopy demonstrated characteristic myelin-like inclusions, most prominently in the podocyte cytoplasm. Slit lamp examination revealed ocular abnormalities including cornea verticillata, conjunctival vessel tortuosity, and posterior subcapsular lenticonular opacities. The electrocardiogram and echocardiogram excluded cardiac involvement. Detailed neurologic examinations and audiogram were normal. X-ray of the left hand showed marked delay in skeletal maturation with the age of 2 years. Bone densitometry demonstrated severe osteoporosis with significant risk of fractures. Because of the multisystem involvement, ERT with agalsidase beta was commenced, which the boy tolerated well.

The patient was followed-up carefully. At 36 months of treatment, he had gained weight and height significantly. His bone age increased from 2 to 6 years. Albuminuria occurred only intermittently, and glomerular filtration rate remained normal. The results of cardiac and neurologic examinations were unremarkable. Plasma and urine GL-3 levels, which were elevated at baseline, were remarkably reduced. However, angiokeratomas increased in size and number (Figure 2a and 2b). The boy has not developed any new sign of FD.

**Discussion**

FD is a devastating, progressive inborn error of glycosphingolipid metabolism. Diagnosis is often delayed because of the rarity of the condition, multisystem involvement and the non-specific nature of many symptoms. Furthermore, the pattern of signs and symptoms may vary significantly among patients, even within the same family.

Observation of angiokeratomas may be one of the first clues to the presence of FD. These characteristic skin lesions are caused by weakening of the capillary wall due to glycosphingolipid accumulation, and subsequent vascular ectasia within the epidermis and dermis. They usually become apparent during childhood or adolescence, and have a predilection for the umbilical region, lower abdomen, buttocks, groin, genital areas and thighs. Angiokeratomas may also occur on mucosal areas, such as the conjunctiva, mouth, and respiratory, gastrointestinal and genitourinary tract [3,4].

Although angiokeratomas can serve as a diagnostic sign, there is no evidence that they could be a prognostic marker. Besides, their importance as ERT effectiveness marker is not established, and published data are sparse and inconsistent. Buongiorno and Pistone [6] reported two patients in whom angiokeratomas remained stable after 12 months of ERT. Tsambaos et al. [7], and Fauchaise et al. [8], observed reduction in both size and number of angiokeratomas during ERT. In contrary, Ries and Schiffman [9] described an increase of angiokeratoma formation is some patients receiving ERT. They also reported that the presence of angiokeratoma was associated with higher risk of end-organ involvement in male children and adolescents.

In our patient with non-classical presentation, angiokeratomas became apparent at a very young age of 5 years. At diagnosis, two years later, he had marked growth retardation, renal involvement and delayed bone age. Initiation of ERT resulted in catch-up growth, skeletal maturation, and reduction of proteinuria. Plasma and urine GL-3 concentrations decreased. Angiokeratomas slowly increased in number and size during the intervening years. Our observation does not support angiokeratomas as a marker of the efficacy of ERT. Further large studies are required to clarify the precise role and effect of ERT on vascular skin lesions in patients with FD.

**Conclusion**

Although cutaneous signs of FD generally appear during childhood, the diagnosis is often delayed or missed. This case confirms that vascular skin lesions could serve as a diagnostic sign in FD. However, in contrary to some previous reports, it does not support angiokeratomas as surrogate marker of the course of the disease or efficacy of ERT.

**Conflict of Interest Statement**

The authors have not received any grant support for the submitted manuscript and do not serve as consultants to Genzyme Corp.

**References**